GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Float Percentage Of Total Shares Outstanding

CNSP (CNS Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 100.03% (As of Jul. 15, 2025)


View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CNS Pharmaceuticals's float shares is 5.46 Mil. CNS Pharmaceuticals's total shares outstanding is 5.46 Mil. CNS Pharmaceuticals's float percentage of total shares outstanding is 100.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CNS Pharmaceuticals's Insider Ownership is 7.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CNS Pharmaceuticals's Institutional Ownership is 0.74%.

CNS Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CNS Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=5.46/5.46
=100.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
CMND ATNF MTNB CERO SILO ICU GLTO AZTR BZYR MBIO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
BE5:Germany
Address
2100 West Loop South, Suite 900, Houston, TX, USA, 77027
Website
https://www.cnspharma.com
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Executives
Christopher Downs officer: Chief Financial Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco director, officer: Chief Executive Officer PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes director 13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027